42 results about "Platelet production" patented technology

Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.

The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.

Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.

Provided is a megakaryocyte and / or platelet production method, enabling to produce a megakaryocyte and / or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and / or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and / or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture. A third invention is a method for producing thrombopoietin, comprising culturing a preadipocyte in a preadipocyte culturing basic medium containing dexamethasone, 3-isobutyl-1-methylxanthine and insulin and collecting thrombopoietin from a culture.

The present invention relates to a synthetic variable region of an immunoglobin construct which contains in at least one of its CDRs a sequence of thrombopoietin, e.g., IEGPTLRQWLAARA or its derivatives. This construct can efficiently bind and activate a thrombopoientin receptor (MPL) leading to stimulation of proliferation, growth or differentiation or modulation of apoptosis of hematopoietic cells, especially platelet progenitor cells. The invention further relates to the use of the synthebody to treat hematopoietic or immune disorders, and particularly thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions.

The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided.Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula:wherein, R1 is a halogen atom or C1-C3 alkyloxy; R2 is C1-C8 alkyl; R3 is C1-C8 alkyl; R4 and R5 are each independently a fluorine atom or chlorine atom; R6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon,a pharmaceutically acceptable salt thereof, or a solvate thereof.

Disclosed is a platelet additive solution (PAS) comprising a viscosity increasing agent. The use of a PAS comprising such a viscosity increasing agent, especially at concentrations effective to achieve a viscosity similar to that of blood plasma, promotes platelet recovery during extraction from pooled buffy coats and provides for easier platelet production by maintaining the red cell / platelet-rich-supernatant interface.

The invention relates to the technical field of machines, in particular to a method for artificially synthesizing platelets in vitro in a fluid movement mode. The method comprises a platelet generating device, a vacuum suction device and a platelet enriching device. According to a device and the method for artificially synthesizing platelets in vitro in a fluid movement mode, a turbulence device can be used to simulate a blood turbulence system in the body, induce platelet production, forcibly block quasi-platelet aggregation, and apply a kinetic energy that forces quasi-platelets to split thequasi-platelets self, so that clean platelets can be obtained, and platelet antibodies do not exist. The platelet yield produced by the method is huge, and there is no significant difference in the aspects of functions between mature platelets in the body and the produced platelets. The produced platelets can be directly applied to the clinic, and since the produced platelets is not screened by an in vivo immune system, the produced platelets are not obvious in antigenic property, and no platelet antibodies are generated.

The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.

A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.

The present invention provides a highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors.

The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.

The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

Provided are methods for increasing platelet response in a subject at risk for bleeding due at least in part to a low platelet count by administering to a subject with a low platelet count an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridine-2-yl)piperidine-4-carboxylic acid.

The invention belongs to the field of genetic engineering and pharmacy, and relates to a thrombopoietin fusion protein, a preparation method and applications thereof, particularly to a fusion proteinof a thrombopoietin mimetic peptide (TMP) diad encoded by a yeast preference codon and human serum albumin (HSA), a preparation method and applications thereof. According to the present invention, thefusion protein contains the HSA molecule and the TMP diad encoded by the yeast preference codon, wherein the HSA molecule is located at the N-terminal of the fusion protein, and the TMP diad encodedby the yeast preference codon is located at the C-terminal of the fusion protein; the fusion protein can be highly and stably expressed in yeast, and can be applied to industrial production; and the fusion protein can significantly promote the platelet production, has long half-life in the human body, and can be used for preparing drugs for treatment of various primary or secondary thrombocytopenia and other diseases.

The invention relates to the mechanical technical field, and in particular, relates to a device for artificially synthesizing platelets in vitro in a fluid motion mode, wherein the device includes a platelet production device, a vacuum suction device and a platelet enrichment device. According to the device and method for artificially synthesizing the platelets in vitro in the fluid motion mode, ablood turbulence system in vivo can be simulated by a self turbulence device, the platelets are induced to produce, quasi platelet aggregation is forcibly prevented, and a kinetic energy to force quasi platelet self-splitting is applied, the clean platelets are obtained, and no platelet antibodies exist. The platelets produced by the method have huge yield and no significant difference from the function of mature platelets in vivo, and can be directly applied in clinic; because of no screening by the immune system in vivo, the produced platelets have no obvious antigenicity and no platelet antibodies are produced.

Disclosed is a method for increasing the number of platelets in a mammal, which comprises administering to the mammal a platelet number increasing effective amount of an unbound, preferably a soluble, MPL receptor.

The invention discloses a method for expressing and purifying a novel cell reprogramming factor. A small ubiquitin-like modifier (SUMO) and a cell penetrating peptide (TAT) are introduced to at the 5'end of a mouse Oct4 gene by a genetic engineering technique. A large number of a TAT-Oct4 protein with a penetrating activity is obtained through in-vitro fusion expression and enzymatic digestion purification, a foundation is laid for the realization of reprogramming cells into iPS cells by using the reprogramming factor protein inducer and the final obtaining of precursor cells for platelet production; and the protein or the nucleotide sequence can be used to induce the production of the iPS cells.

The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.

Disclosed herein are compounds, compositions and methods for using such compounds and compositions in the treatment of hyperproliferative conditions, including precancerous and cancerous conditions. In one embodiment, the compounds include resonance modulating compounds that can be used in the method as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. Such resonance modulators have inherent electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of resonance modulators are disclosed, and these substances generally possess resonating intramolecular dipole moments that are capable of electrostatic interaction with biological environments. In certain examples the compounds aggregate at sites of therapeutic action to enhance their therapeutic activity. In other examples the compounds stimulate platelet production.

The invention discloses an application of histone methyltransferase inhibitor to preparation of a product for promoting megakaryocyte proliferation or blood platelet formation. The histone methyltransferase inhibitor is a histone methyltransferase G9a inhibitor. The histone methyltransferase G9a inhibitor stated in the invention can be used for promoting single CD34+hematopoietic stem and progenitor cells to differentiate and form 400 CD41a+CD42b+platelet granules, and the platelet granules are increased by 10 times than the platelet granules of a control group; the thrombopoiesis efficiency is further higher than the general range in literature report obviously, and a foundation is laid for mass production of functional platelets for clinic treatment in the future.